Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

320.56 -1.50 (-0.46%)
Streaming Delayed Price Updated: 9:33 AM EDT, Jul 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
3 biotech powerhouses poised to thrive amid sector rebound
If the newfound support and uptrend in the biotech sector last, as the new year quickly approaches, the biotech sector could shift from lagger to leader. 
Via MarketBeat
Topics ETFs
Analyst Expectations for Alnylam Pharmaceuticals's Future
Via Benzinga
Alnylam to Webcast Virtual R&D Day
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Expert Ratings for Alnylam Pharmaceuticals
Via Benzinga
Earnings Outlook For Alnylam Pharmaceuticals
Via Benzinga
Expert Ratings for Alnylam Pharmaceuticals
Via Benzinga
Why Newly Listed Korro Bio Shares Are Gaining Today
H.C. Wainwright initiated coverage on Korro Bio Inc (NASDAQ: KRRO), a biotech company developing genetic medicines focused on editing ribonucleic acid (RNA) to treat various diseases. 
Via Benzinga
Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2023
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Analyst Expectations for Alnylam Pharmaceuticals's Future
Via Benzinga
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shareholder Alert: Investigation over Possible Violations of Securities Laws
San Diego, CA -- (SBWIRE) -- 11/08/2023 -- Alnylam Pharmaceuticals, Inc is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Recognized by Science Magazine as Top Employer for Fifth Consecutive Year
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Conference Call Discussing Third Quarter 2023 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing
The company can begin a pivotal study of its treatment for cardiomyopathy. 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
CSX To Rally Around 27%? Here Are 10 Other Analyst Forecasts For Wednesday
Morgan Stanley cut Netflix, Inc. (NASDAQ: NFLX) price target from $450 to $430. Morgan Stanley analyst Benjamin Swinburne maintained an Equal-Weight rating. Netflix shares rose 0.8% to $375.51 in... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2023
Via Benzinga
Why Is Genetic Disease-Focused Alnylam Pharmaceuticals Stock Trading Lower Today?
The FDA has issued a Complete Response Letter (CRL) to Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) supplemental New Drug Application (sNDA) for patisiran for cardiomyopathy of transthyretin- 
Via Benzinga
Alnylam Stock Crumbles After The FDA Unexpectedly Rejects Its Heart Drug
Shares skidded to their lowest point since September on the FDA's rejection. 
Via Investor's Business Daily
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
2 Growth Stocks That Could Rocket Higher Before the End of 2023
Potential approvals of new medicines expected soon could push these stocks through the roof. 
Via The Motley Fool
Alnylam to Present Additional Data for Patisiran in Patients With the Cardiomyopathy of ATTR Amyloidosis, Including 24-Month Results From the APOLLO-B Phase 3 Study, at the Heart Failure Society of America Annual Scientific Meeting 2023
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023
Via Benzinga
Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges
Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.